Surrogate markers of infection: Interrogation of the immune system

Biomarkers in Medicine

Volumn 5, Issue 2, 2011, Pages 131-148

  Chakera, Aron ^a   Lucas, Andrew ^b   Lucas, Michaela ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MURDOCH UNIVERSITY   (Australia)

^c PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

adaptive immunity; biomarker; cytomegalovirus; innate immunity; tuberculosis

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GANCICLOVIR; GENOTYPE (DRUG); INTERLEUKIN 2; ISONIAZID; KHELLIN; NEOPTERIN; PENTRAXIN 3; PROCALCITONIN; RIFAMPICIN; TACROLIMUS; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; XPERT;

BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSPOT ASSAY; ESOPHAGITIS; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INFECTION CONTROL; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PNEUMONIA; RETINITIS; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SHORT COURSE THERAPY; T LYMPHOCYTE; TUBERCULOSIS; VIREMIA;

BIOLOGICAL MARKERS; COMMUNICABLE DISEASES; CYTOMEGALOVIRUS; HUMANS; IMMUNE SYSTEM; MYCOBACTERIUM TUBERCULOSIS;

CYTOMEGALOVIRUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 79953837236     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.17     Document Type: Review

References (149)

1. Atkinson AJ, Colburn WA, Degruttola VG et al.: Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001). (Pubitemid 32225406)
2. Fend R, Kolk AHJ, Bessant C, Buijtels P, Klatser PR, Woodman AC: Prospects for clinical application of electronic-nose technology to early detection of Mycobacterium tuberculosis in culture and sputum. J. Clin. Microbiol. 44, 2039-2045 (2006). (Pubitemid 43902150)
3. Phillips M, Cataneo RN, Condos R et al.: Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb.) 87, 44-52 (2007). (Pubitemid 44960164)
4. Weetjens BJC, Mgode GF, Machang'u RS et al.: African pouched rats for the detection of pulmonary tuberculosis in sputum samples. Int. J. Tuberc Lung Dis. 13, 737-743 (2009).
5. Cotran RS, Kumar V, Collins T: Pathologic Basis of Disease (6th Edition). WB Saunders Co., PA, USA, 50-88 (1999).
6. Scharff RL: Health-Related Costs from Foodborne Illness in the United States. Pew Trust, Washington, DC, USA (2010).
7. Morris K: WHO recommends against inaccurate tuberculosis tests. Lancet 377, 113-114 (2011).
8. Ghildyal R, Dagher H, Donninger H et al.: Rhinovirus infects primary human airway fbroblasts and induces a neutrophil chemokine and a permeability factor. J. Med. Virol. 75(4), 608-615 (2005). (Pubitemid 40293530)
9. Bahrami B, Macfarlane S, Macfarlane GT: Induction of cytokine formation by human intestinal bacteria in gut epithelial cell lines. J. Appl. Microbiol. 110(1), 353-363 (2011).
10. Saitoh T, Akira S: Regulation of innate immune responses by autophagy-related proteins. J. Cell Biol. 189(6), 925-935 (2010).
11. Shapira SD, Gat-Viks I, Shum BO et al.: A physical and regulatory map of host-infuenza interactions reveals pathways in H1N1 infection. Cell 139(7), 1255-1267 (2009).
12. Geijtenbeek TB, Gringhuis SI: Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9(7), 465-479 (2009).
13. Metzger J, Kirsch T, Schiffer E et al.: Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 78(12), 1252-1262 (2010).
14. Saiki RK, Scharf S, Faloona F et al.: Enzymatic amplifcation of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. 1985. Biotechnology 24, 476-480 (1992).
15. Naber SP: Molecular pathology-diagnosis of infectious disease. N. Engl. J. Med. 331(18), 1212-1215 (1994).
16. Lewis JS, Fakile O, Foss E et al.: Direct DNA probe assay for Neisseria gonorrhoeae in pharyngeal and rectal specimens. J. Clin. Microbiol. 31(10), 2783-2785 (1993). (Pubitemid 23284922)
17. Musial CE, Tice LS, Stockman L, Roberts GD: Identifcation of mycobacteria from culture by using the Gen-Probe Rapid Diagnostic System for Mycobacterium avium complex and Mycobacterium tuberculosis complex. J. Clin. Microbiol. 26(10), 2120-2123 (1988).
18. Drake TA, Hindler JA, Berlin OG, Bruckner DA: Rapid identifcation of Mycobacterium avium complex in culture using DNA probes. J. Clin. Microbiol. 25(8), 1442-1445 (1987). (Pubitemid 17098716)
19. Twin J, Taylor N, Garland SM et al.: A comparison of two Mycoplasma genitalium real-time polymerase chain reaction detection methodologies. J. Clin. Microbiol. 49(3), 1140-1142 (2011).
20. Smalling TW, Sefers SE, Li H, Tang YW: Molecular approaches to detecting herpes simplex virus and enteroviruses in the central nervous system. J. Clin. Microbiol. 40(7), 2317-2322 (2002). (Pubitemid 34747326)
21. D'amato RF, Wallman AA, Hochstein LH et al.: Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test. J. Clin. Microbiol. 33(7), 1832-1834 (1995).
22. Greisen K, Loeffelholz M, Purohit A, Leong D: PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fuid. J. Clin. Microbiol. 32, 335-351 (1994). (Pubitemid 24033893)
23. Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I: Effects of heparin on polymerase chain reaction for blood white cells. J. Clin. Lab. Anal. 13(3), 133-140 (1999). (Pubitemid 29207139)
24. Holodniy M, Mole L, Yen-Lieberman B et al.: Comparative stabilities of quantitative human immunodefciency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J. Clin. Microbiol. 33(6), 1562-1566 (1995).
25. Orenbuch-Harroch E, Levy L,Ben-Chetrit E: Acute hepatitis B or exacerbation of chronic hepatitis B-that is the question. World J. Gastroenterol. 14(46), 7133-7137 (2008).
26. Berry MP, Graham CM, Mcnab FW et al.: An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010).
27. Freeman RB: The 'indirect' effects of cytomegalovirus infection. Am. J. Transplant. 9, 2453-2458 (2009).
28. Brennan DC: Cytomegalovirus in renal transplantation. J. Am. Soc Nephrol. 12(4), 848-855 (2001). (Pubitemid 32246715)
29. Peggs KS: Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin. Biol. Ther. 9, 725-736 (2009).
30. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH: Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72(Pt 9), 2059-2064 (1991).
31. Mcvoy MA, Adler SP: Immunologic evidence for frequent age-related cytomegalovirus reactivation in seropositive immunocompetent individuals. J. Infect. Dis. 160(1), 1-10 (1989). (Pubitemid 19162986)
32. Gurkan S, Luan Y, Dhillon N et al.: Immune reconstitution following rabbit antithymocyte globulin. Am. J. Transplant. 10(9), 2132-2141 (2010).
33. Sagedal S, Nordal KP, Hartmann A et al.: The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant. 2(9), 850-856 (2002). (Pubitemid 36306840)
34. Sagedal S, Hartmann A, Nordal KP et al.: Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 66(1), 329-337 (2004). (Pubitemid 38870110)
35. Ginns LC, Cosimi AB, Morris PJ: Immunosuppression in Transplantation. Blackwell Science, Boston, MA, USA (1999).
36. Chandler SH, Handsfeld HH, McDougall JK: Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. J. Infect. Dis. 155(4), 655-660 (1987). (Pubitemid 17052986)
37. Collier AC, Chandler SH, Handsfeld HH, Corey L, McDougall JK: Identifcation of multiple strains of cytomegalovirus in homosexual men. J. Infect. Dis. 159(1), 123-126 (1989). (Pubitemid 19022007)
38. Bale JF Jr, Petheram SJ, Souza IE, Murph JR: Cytomegalovirus reinfection in young children. J. Pediatr. 128(3), 347-352 (1996). (Pubitemid 26087534)
39. Nemati E, Eizadi M, Lankarani MM et al.: Cytomegalovirus disease after kidney transplantation: clues to accurate diagnosis. Transplant Proc 39(4), 987-989 (2007). (Pubitemid 46764913)
40. Arthurs SK, Eid AJ, Pedersen RA et al.: Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. 46(6), 840-846 (2008). (Pubitemid 351417184)
41. Weimar W, Metselaar HJ, Balk AH, Mochtar B, Rothbarth PH, Jeekel J: Passive immunization to prevent cytomegalovirus disease after kidney and heart transplantation. Transplant Proc 22(1), 229-232 (1990). (Pubitemid 20112833)
42. Mayoral JL, Brayman KL, Gillingham KJ, Sutherland DE, Najarian JS, Dunn DL: Infuence of pretransplant cytomegalovirus serology and treatment of rejection upon disease after kidney and kidney plus pancreas transplantation. Transplant Proc 24(3), 929-931 (1992).
43. Giral M, Nguyen JM, Daguin P et al.: Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J. Am. Soc Nephrol. 12(8), 1758-1763 (2001). (Pubitemid 32674440)
44. Dunn W, Chou C, Li H et al.: Functional profling of a human cytomegalovirus genome. Proc Natl Acad. Sci. USA 100(24), 14223-14228 (2003). (Pubitemid 37499218)
45. Pereyra F, Rubin RH: Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr. Opin. Infect. Dis. 17, 357-361 (2004). (Pubitemid 39037531)
46. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, Früh K: Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad. Sci. USA 93, 10990-10995 (1996). (Pubitemid 26333105)
47. Schrier RD, Rice GP, Oldstone MB: Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J. Infect. Dis. 153, 1084-1091 (1986). (Pubitemid 16086776)
48. Frascaroli G, Varani S, Blankenhorn N et al.: Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor. J. Immunol. 182, 477-488 (2009).
49. Falagas ME, Snydman DR, Griffth J, Werner BG: Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin. Infect. Dis. 23(3), 468-474 (1996). (Pubitemid 26304492)
50. Hjelmesaeth J, Sagedal S, Hartmann A et al.: Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 47(9), 1550-1556 (2004). (Pubitemid 39371637)
51. Fishman JA, Rubin RH: Infection in organ-transplant recipients. N. Engl. J. Med. 338, 1741-1751 (1998). (Pubitemid 28268592)
52. Khoury JA, Storch GA, Bohl DL et al.: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant. 6(9), 2134-2143 (2006). (Pubitemid 44199547)
53. Manez R, St George K, Linden P et al.: Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis. J. Clin. Microbiol. 32(11), 2655-2659 (1994). (Pubitemid 24319097)
54. Boland GJ, De Gast GC, Hene RJ et al.: Early detection of active cytomegalovirus (CMV) infection after heart and kidney transplantation by testing for immediate early antigenemia and infuence of cellular immunity on the occurrence of CMV infection. J. Clin. Microbiol. 28(9), 2069-2075 (1990). (Pubitemid 20260991)
55. Van Den Berg AP, Van Son WJ, Van Der Bij W, Van Der Giessen M, The TH: Early identifcation of patients at high risk of severe cytomegalovirus disease after renal transplantation using the immediate early antigenemia assay. Transplant Proc 22(4), 1800-1802 (1990). (Pubitemid 20284541)
56. Humar A, Kumar D, Boivin G, Caliendo AM: Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J. Infect. Dis. 186(6), 829-833 (2002). (Pubitemid 35013436)
57. Pawelec G, Derhovanessian E: Role of CMV in immune senescence. Virus Res. (2010) (Epub ahead of print).
58. Helantera I, Teppo AM, Koskinen P, Tornroth T, Gronhagen-Riska C, Lautenschlager I: Increased urinary excretion of transforming growth factor-β (1) in renal transplant recipients during cytomegalovirus infection. Transpl. Immunol. 15(3), 217-221 (2006). (Pubitemid 43129388)
59. Helantera I, Loginov R, Koskinen P, Tornroth T, Gronhagen-Riska C, Lautenschlager I: Persistent cytomegalovirus infection is associated with increased expression of TGF-β1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol. Dial. Transplant 20(4), 790-796 (2005). (Pubitemid 40520658)
60. Slobedman B, Stern JL, Cunningham AL, Abendroth A, Abate DA, Mocarski ES: Impact of human cytomegalovirus latent infection on myeloid progenitor cell gene expression. J. Virol. 78(8), 4054-4062 (2004). (Pubitemid 38437212)
61. Kondo K, Xu J, Mocarski ES: Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad. Sci. USA 93(20), 11137-11142 (1996). (Pubitemid 26333131)
62. Kubat NJ, Tran RK, McAnany P, Bloom DC: Specifc histone tail modifcation and not DNA methylation is a determinant of herpes simplex virus type 1 latent gene expression. J. Virol. 78(3), 1139-1149 (2004). (Pubitemid 38095824)
63. Sinclair J, Sissons P: Latency and reactivation of human cytomegalovirus. J. Gen. Virol. 87(Pt 7), 1763-1779 (2006). (Pubitemid 43985862)
64. Groves IJ, Reeves MB, Sinclair JH: Lytic infection of permissive cells with human cytomegalovirus is regulated by an intrinsic 'pre-immediate-early' repression of viral gene expression mediated by histone post-translational modifcation. J. Gen. Virol. 90(Pt 10), 2364-2374 (2009).
65. Reusser P, Riddell SR, Meyers JD, Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78(5), 1373-1380 (1991).
66. + cytotoxic T-lymphocytes in liver transplant patients. Transplantation 69(11), 2251-2259 (2000). (Pubitemid 30408985)
67. Cwynarski K, Ainsworth J, Cobbold M et al.: Direct visualization of cytomegalovirus-specifc T-cell reconstitution after allogeneic stem cell transplantation. Blood 97(5), 1232-1240 (2001). (Pubitemid 32183744)
68. Hebart H, Daginik S, Stevanovic S et al.: Sensitive detection of human cytomegalovirus peptide-specifc cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and fow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99(10), 3830-3837 (2002). (Pubitemid 34534558)
69. + T-cell immunity to cytomegalovirus. Hum. Immunol. 65(5), 456-464 (2004). (Pubitemid 38686770)
70. Khan N, Hislop A, Gudgeon N et al.: Herpesvirus-specifc CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J. Immunol. 173(12), 7481-7489 (2004). (Pubitemid 39628188)
71. + T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202(5), 673-685 (2005). (Pubitemid 41248418)
72. + T-cell repertoire. J. Virol. 81(14), 7759-7765 (2007). (Pubitemid 47047862)
73. Walter EA, Greenberg PD, Gilbert MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333 (16), 1038-1044 (1995).
74. Einsele H, Roosnek E, Rufer N et al.: Infusion of cytomegalovirus (CMV)-specifc T cells for the treatment of CMV infection not responding to antiviral chemotherapy Blood 99(11), 3916-3922 (2002). (Pubitemid 35332029)
75. Peggs KS, Verfuerth S, Pizzey A et al.: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specifc T-cell lines. Lancet 362(9393), 1375-1377 (2003). (Pubitemid 37338339)
76. Cobbold M, Khan N, Pourgheysari B et al.: Adoptive transfer of cytomegalovirus-specifc CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202(3), 379-386 (2005). (Pubitemid 41126955)
77. Valentine VG, Weill D, Gupta MR et al.: Ganciclovir for cytomegalovirus: a call for indefnite prophylaxis in lung transplantation. J. Heart Lung Transplant. 27(8), 875-881 (2008).
78. Dunachie SJ, Berthoud T, Keating SM, Hill AV, Fletcher HA: MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and effcacy. PLoS One 5(9), e12557 (2010).
79. + T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 45(3), 543-549 (2010).
80. Araki K, Gangappa S, Dillehay DL, Rouse BT, Larsen CP, Ahmed R: Pathogenic virus-specifc T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. J. Exp. Med. 207(11), 2355-2367 (2010).
81. Compton T, Kurt-Jones EA, Boehme KW et al.: Human cytomegalovirus activates infammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol. 77(8), 4588-4596 (2003). (Pubitemid 36402808)
82. Cervera C, Balderramo D, Suarez B et al.: Donor mannose-binding lectin gene polymorphisms infuence the outcome of liver transplantation. Liver Transpl. 15(10), 1217-1224 (2009).
83. Cervera C, Lozano F, Linares L et al.: Infuence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation. Transplant Proc 41(6), 2259-2261 (2009).
84. Hu Y, Wu D, Tao R, Shang S: Association between mannose-binding lectin gene polymorphism and pediatric cytomegalovirus infection. Viral Immunol. 23(4), 443-447 (2010).
85. Lodoen M, Ogasawara K, Hamerman JA et al.: NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197(10), 1245-1253 (2003). (Pubitemid 36617771)
86. Bekiaris V, Gaspal F, Mcconnell FM et al.: NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism. Eur. J. Immunol. 39(10), 2800-2808 (2009).
87. Cervera C, Lozano F, Saval N et al.: The infuence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 83(11), 1493-1500 (2007). (Pubitemid 46934073)
88. Frascaroli G, Varani S, Mastroianni A et al.: Dendritic cell function in cytomegalovirus-infected patients with mononucleosis. J. Leukoc Biol. 79(5), 932-940 (2006). (Pubitemid 44835580)
89. Benedict CA, Loewendorf A, Garcia Z, Blazar BR, Janssen EM: Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway J. Immunol. 180(7), 4836-4847 (2008).
90. Lochmanova A, Lochman I, Tomaskova H et al.: QuantiFERON-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc. 42(9), 3574-3577 (2010).
91. Wallis RS, Pai M, Menzies D et al.: Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375(9729), 1920-1937 (2010).
92. Lonnroth K, Raviglione M: Global epidemiology of tuberculosis: prospects for control. Semin. Respir. Crit. Care Med. 29(5), 481-491 (2008).
93. Corbett EL, Marston B, Churchyard GJ, De Cock KM: Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367(9514), 926-937 (2006).
94. Wright A, Zignol M, Van Deun A et al.: Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373(9678), 1861-1873 (2009).
95. Raviglione MC, Pio A: Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 359(9308), 775-780 (2002). (Pubitemid 34215081)
96. Maher D, Dye C, Floyd K et al.: Planning to improve global health: the next decade of tuberculosis control. Bull. World Health Organ. 85(5), 341-347 (2007). (Pubitemid 46718357)
97. Russell DG, Barry CE 3rd, Flynn JL: Tuberculosis: what we don't know can, and does, hurt us. Science 328(5980), 852-856 (2010).
98. Lucas M, Nicol P, McKinnon E et al.: A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 65(5), 442-448 (2010).
99. Berrington WR, Hawn TR: Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? Immunol. Rev. 219, 167-186 (2007). (Pubitemid 47390000)
100. Constantoulakis P, Filiou E, Rovina N et al.: In vivo expression of innate immunity markers in patients with Mycobacterium tuberculosis infection. BMC Infect. Dis. 10, 243 (2010).
101. Chen YC, Hsiao CC, Chen CJ et al.: Toll-like receptor 2 gene polymorphisms, pulmonary tuberculosis, and natural killer cell counts. BMC Med. Genet. 11, 17 (2010).
102. Wallis RS, Helfand MS, Whalen CC et al.: Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis. Tuber. Lung Dis. 77(6), 516-523 (1996). (Pubitemid 27023149)
103. Immanuel C, Rajeswari R, Rahman F, Kumaran PP, Chandrasekaran V, Swamy R: Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. Int. J. Tuberc Lung Dis. 5(2), 185-190 (2001). (Pubitemid 32401864)
104. Turgut T, Akbulut H, Deveci F, Kacar C, Muz MH: Serum interleukin-2 and neopterin levels as useful markers for treatment of active pulmonary tuberculosis. Tohoku. J. Exp. Med. 209(4), 321-328 (2006). (Pubitemid 44144901)
105. Fuchs D, Hausen A, Kofer M, Kosanowski H, Reibnegger G, Wachter H: Neopterin as an index of immune response in patients with tuberculosis. Lung 162(6), 337-346 (1984). (Pubitemid 15223278)
106. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM: Biomarkers for TB treatment response: challenges and future strategies. J. Infect. 57(2), 103-109 (2008).
107. Djoba Siawaya JF, Bapela NB, Ronacher K et al.: Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J. Infect. 56(5), 340-347 (2008).
108. Eugen-Olsen J, Gustafson P, Sidenius N et al.: The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int. J. Tuberc Lung Dis. 6(8), 686-692 (2002). (Pubitemid 34832148)
109. Azzurri A, Sow OY, Amedei A et al.: IFN-γ-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring infammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 7(1), 1-8 (2005). (Pubitemid 40431338)
110. Baylan O, Balkan A, Inal A et al.: The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J. Infect. Dis. 59(3), 164-167 (2006). (Pubitemid 43959973)
111. Nyamande K, Lalloo UG: Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int. J. Tuberc Lung Dis. 10(5), 510-515 (2006). (Pubitemid 43667638)
112. Prat C, Dominguez J, Andreo F et al.: Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J. Infect. 52(3), 169-177 (2006). (Pubitemid 43286182)
113. Schleicher GK, Herbert V, Brink A et al.: Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur. Respir. J. 25(4), 688-692 (2005). (Pubitemid 40528763)
114. Kandemir O, Uluba B, Polat G, Sezer C, Camdeviren H, Kaya A: Elevation of procalcitonin level in patients with pulmonary tuberculosis and in medical staff with close patient contact. Arch. Med. Res. 34(4), 311-314 (2003). (Pubitemid 37075843)
115. Jacobsen M, Repsilber D, Gutschmidt A et al.: Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J. Mol. Med. 85(6), 613-621 (2007). (Pubitemid 46876510)
116. Maertzdorf J, Repsilber D, Parida SK et al.: Human gene expression profles of susceptibility and resistance in tuberculosis. Genes Immun. 12(1), 15-22 (2010).
117. Doherty M, Wallis RS, Zumla A: Biomarkers for tuberculosis disease status and diagnosis. Curr. Opin. Pulm. Med. 15(3), 181-187 (2009).
118. Almeida AS, Lago PM, Boechat N et al.: Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity J. Immunol. 183(1), 718-731 (2009).
119. Thomas MM, Hinks TS, Raghuraman S et al.: Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fuid antigen-specifc T-cells. Int. J. Tuberc Lung Dis. 12(6), 651-657 (2008). (Pubitemid 351846763)
120. Jafari C, Thijsen S, Sotgiu G et al.: Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study Am. J. Respir. Crit. Care Med. 180(7), 666-673 (2009).
121. Semmo N, Lucas M, Krashias G, Lauer G, Chapel H, Klenerman P: Maintenance of HCV-specifc T-cell responses in antibody-defcient patients a decade after early therapy Blood 107(11), 4570-4571 (2006). (Pubitemid 43801387)
122. Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149(3), 177-184 (2008).
123. Lalvani A: Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy Chest 131(6), 1898-1906 (2007). (Pubitemid 46981652)
124. Casey R, Blumenkrantz D, Millington K et al.: Enumeration of functional T-cell subsets by fuorescence-immunospot defnes signatures of pathogen burden in tuberculosis. PLoS One 5(12), e15619 (2010).
125. + T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 40(8), 2211-2220 (2010).
126. Bellofore B, Matarese A, Balato N et al.: Prevention of tuberculosis in patients taking tumor necrosis factor-α blockers. J. Rheumatol. Suppl. 83, 76-77 (2009).
127. Lyashchenko K, Colangeli R, Houde M, Al Jahdali H, Menzies D, Gennaro ML: Heterogeneous antibody responses in tuberculosis. Infect. Immun. 66(8), 3936-3940 (1998). (Pubitemid 28347858)
128. Wu X, Yang Y, Zhang J et al.: Humoral immune responses against the Mycobacterium tuberculosis 38-kilodalton, MTB48, and CFP-10/ESAT-6 antigens in tuberculosis. Clin. Vaccine Immunol. 17(3), 372-375 (2010).
129. Kunnath-Velayudhan S, Salamon H, Wang HY et al.: Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad. Sci. USA 107(33), 14703-14708 (2010).
130. Schluger NW, Rom WN: Current approaches to the diagnosis of active pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 149(1), 264-267 (1994). (Pubitemid 24066130)
131. Fitzwater SP, Caviedes L, Gilman RH et al.: Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin. Infect. Dis. 51(4), 371-378 (2010).
132. Robledo JA, Mejia GI, Morcillo N et al.: Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multi-center study. Int. J. Tuberc Lung Dis. 10(6), 613-619 (2006). (Pubitemid 43845021)
133. Shah NS, Moodley P, Babaria P et al.: Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay. Am. J. Respir. Crit Care Med. (2011) (Epub ahead of print).
134. Abate G, Aseffa A, Selassie A et al.: Direct colorimetric assay for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 42(2), 871-873 (2004). (Pubitemid 38222685)
135. Affolabi D, Sanoussi N, Odoun M et al.: Rapid detection of multidrug-resistant Mycobacterium tuberculosis in Cotonou (Benin) using two low-cost colorimetric methods: resazurin and nitrate reductase assays. J. Med. Microbiol. 57(Pt 8), 1024-1027 (2008).
136. Church LD, Cook GP, Mcdermott MF: Primer: infammasomes and interleukin 1β in infammatory disorders. Nat. Clin. Pract. Rheumatol. 4(1), 34-42 (2008).
137. Kikly K, Liu L, Na S, Sedgwick JD: The IL-23/Th(17) axis: therapeutic targets for autoimmune infammation. Curr. Opin. Immunol. 18(6), 670-675 (2006). (Pubitemid 44635178)
138. Ge D, Fellay J, Thompson AJ et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
139. Weinmann AS, Yan PS, Oberley MJ, Huang TH, Farnham PJ: Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev. 16(2), 235-244 (2002). (Pubitemid 34075815)
140. Sheldon S, Riches P, Gooding R, Soni N, Hobbs JR: C-reactive protein and its cytokine mediators in intensive-care patients. Clin. Chem. 39(1), 147-150 (1993). (Pubitemid 23034976)
141. Whang KT, Steinwald PM, White JC et al.: Serum calcitonin precursors in sepsis and systemic infammation. J. Clin. Endocrinol. Metab. 83(9), 3296-3301 (1998). (Pubitemid 28500975)
142. Zhang D, Lavaux T, Voegeli AC et al.: Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin. Chem. 54(9), 1497-1503 (2008).
143. Mohkam M, Asgarian F, Fahimzad A, Sharifan M, Dalirani R, Abdollah Gorgi F: Diagnostic potential of urinary TNF-α in children with acute pyelonephritis. Iran J. Kidney Dis. 3(2), 89-92 (2009).
144. Ruhwald M, Bodmer T, Maier C et al.: Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur. Respir. J. 32(6), 1607-1615 (2008).
145. Skinner LJ, Chatterton JM, Joss AW, Moir IL, Ho-Yen DO: The use of an IgM immunosorbent agglutination assay to diagnose congenital toxoplasmosis. J. Med. Microbiol. 28(2), 125-128 (1989). (Pubitemid 19054181)
146. WHO: Global tuberculosis control-surveillance, planning, fnancing. WHO Report 2008 www.who.int/tb/publications/global- report/2008/en/
147. WHO: WHO Tuberculosis programme. Framework for effective tuberculosis control http://whqlibdoc.who.int/hq/1994/WHO- TB-94.179.pdf
148. WHO: The stop TB strategy www.who.int/tb/strategy/en/
149. National Health Service: The Mantoux test: Administration, reading and interpretation www.devonpct.nhs.uk/Library/Immunisation-Team/Mantoux%20Test%20 Factsheet.pdf